RxDoctor Payments Data

Jean Wong, MD

Urology · Meriden, CTNPI 1891988648

Payments from drug & device makers

$444in general payments, 2019–2025

Across 15 payments — averaging $29.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$106
  • C. R. Bard, Inc. & Subsidiaries$103
  • Pfizer$90
  • Dentsply IH AB$55
  • Endo Pharmaceuticals Inc.$32
  • Urogen Pharma, Inc.$23
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$37184%
  • Education$7316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$444 in reported general payments places this provider in the 25th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$69,107
Medicare patients
236
Services billed
1,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron135$85,215
GemtesaVibegron48$24,847
Methenamine Hippurate155$9,907
PremarinEstrogens, Conjugated22$9,840
Mirabegron ErMirabegron11$6,596
Solifenacin Succinate110$6,025
Silodosin68$4,358
Tamsulosin Hcl216$2,610
Alfuzosin Hcl ErAlfuzosin Hcl78$1,560
Testosterone14$1,425
Finasteride148$1,296
Estradiol24$1,079
Oxybutynin Chloride ErOxybutynin Chloride70$959
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$267
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim95$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$90$9,84022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 156 urology providers in Connecticut.

Other urology in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →